A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
about
Pancreatic Cancer from Molecular Pathways to Treatment OpinionPancreatic cancer from bench to bedside: molecular pathways and treatment optionsMolecular therapeutics in pancreas cancerIs metastatic pancreatic cancer an untargetable malignancy?State of the art biological therapies in pancreatic cancerNovel agents for advanced pancreatic cancerImmunotherapy of Childhood SarcomasMechanisms of action of therapeutic antibodies for cancerGemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer.Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapyCombination therapy in combating cancer.Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.New targeted therapies in pancreatic cancer.microRNA-218 promotes gemcitabine sensitivity in human pancreatic cancer cells by regulating HMGB1 expressionMicelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.The Somatotropic Axis in Human Aging: Framework for the Current State of Knowledge and Future ResearchAugmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insightsMinireview: Were the IGF Signaling Inhibitors All Bad?Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination StudiesNew therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?Epigenetics of epithelial-to-mesenchymal transition in pancreatic carcinoma.Emerging antibodies for the treatment of pancreatic cancer.Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials.Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome.Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy.Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer.Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review.
P2860
Q26743482-7F954D96-5047-4BDE-BF37-9C7735093209Q26747524-A45D28BC-F426-41F9-9DA4-614C2B901A48Q26751709-6B2DE2A3-7D51-4F96-AB51-5CD250EFB4A5Q26753849-902E9955-D67C-4039-ABBC-1239CA30E7B6Q26769941-DD94AFA9-F9B9-4E56-9905-24754A0BAB65Q26787087-BB5D3E74-6712-46A0-A8BB-684833B74E41Q26795369-B442B4C8-C6C4-4B0A-8B62-BD1557C4F7FAQ28385366-7D44A4B4-CEED-43A1-B79B-2958936AC011Q30235450-F19490EE-9A70-408A-B34D-A3E7FDF5F7C5Q30313824-3894AEA4-0B7F-47C0-80ED-5E3BAB28BA29Q33424008-3D43684C-4DE4-4EC4-8942-D57414C9872DQ33710179-AAC6D8C7-432F-489F-829A-38D2158E1077Q33914234-20F7A693-92B2-41D0-B804-5C111018F466Q34127857-E7192B94-4777-402D-A4D8-100A8B08E04AQ35651453-C328BC73-C60E-4A84-8FB6-8FF4E742297EQ35812824-1C15138F-1163-4261-9C27-4DA08011C966Q36984038-66EEF12E-7F71-4C2B-8ACA-18382B00687EQ37035744-ED58A612-5BE9-4059-9765-FB39A183A969Q37565014-FB793BBC-15F7-452F-BF54-71A051E583DBQ37615933-D08FA3A9-88AE-4919-B169-2979C029B49CQ38586367-32D16A3B-C1A0-48DF-AC76-FAD240458ECCQ38641329-58F7DCE9-4CB0-4394-B7C7-FEC6BD4D2A63Q38645930-65AE174C-D535-4924-9E11-A80A826730A9Q38764039-D7A9EFBD-52E0-4699-9831-4ACE73A967B3Q38850605-0B762E72-B9ED-4F4C-B246-05C744A21F59Q39022032-CD103242-96C8-46A3-9368-E79B0A1387BAQ39108676-17B3F393-0AB3-478F-B959-377D207092E5Q39158427-70A56401-E39B-479E-B4FD-35DB57E596C2Q39233456-FE1DF948-4B64-4D71-A2E6-C2F1D5ECB788Q39390859-4F50BAD7-D2D9-4C73-8C6B-D5CB5B819A8CQ42695251-1F4E9A8E-091C-4A62-87E1-EFE8578945FAQ45249684-904AD20E-EB49-4399-9357-8FC0BA92C1D1Q47735303-FBB3B61F-1A4D-4557-8DE9-D0EB3A358C70Q50314975-8348A2D0-CFFC-4645-8287-74395D7557EBQ54974100-8972B74F-567B-4DDF-AE6F-5CC9B4812535
P2860
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A phase 3 randomized, double-b ...... the pancreas: the GAMMA trial.
@ast
A phase 3 randomized, double-b ...... the pancreas: the GAMMA trial.
@en
type
label
A phase 3 randomized, double-b ...... the pancreas: the GAMMA trial.
@ast
A phase 3 randomized, double-b ...... the pancreas: the GAMMA trial.
@en
prefLabel
A phase 3 randomized, double-b ...... the pancreas: the GAMMA trial.
@ast
A phase 3 randomized, double-b ...... the pancreas: the GAMMA trial.
@en
P2093
P2860
P921
P356
P1433
P1476
A phase 3 randomized, double-b ...... the pancreas: the GAMMA trial.
@en
P2093
A Świeboda-Sadlej
B Melichar
C Szczylik
E Van Cutsem
J L Gansert
P2860
P304
P356
10.1093/ANNONC/MDV027
P50
P577
2015-01-21T00:00:00Z